ResMed
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Sale
QUINN MICHAEL A director
ResMed Common Stock 4,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
BARTLETT CHRISTOPHER director
ResMed Common Stock 15,000 N/A N/A
Option
BARTLETT CHRISTOPHER director
ResMed Options 15,000 N/A N/A
Option
BARTLETT CHRISTOPHER director
ResMed Common Stock 15,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
SMITH ADRIAN M officer: COO Europe
ResMed Common Stock 3,000 N/A N/A
Option
SMITH ADRIAN M officer: COO Europe
ResMed Options 3,000 N/A N/A
Option
SMITH ADRIAN M officer: COO Europe
ResMed Common Stock 3,000 N/A N/A
Option
MCCARTHY DONAGH director
ResMed Common Stock 14,000 N/A N/A
Sale
MCCARTHY DONAGH director
ResMed Common Stock 14,000 N/A N/A
Option
MCCARTHY DONAGH director
ResMed Options 14,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Option
ROBERTS CHRISTOPHER G other: Retired Director
ResMed Common Stock 40,000 N/A N/A
Option
ROBERTS CHRISTOPHER G other: Retired Director
ResMed Options 40,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
QUINN MICHAEL A director
ResMed Common Stock 2,000 N/A N/A
Option
EISEN PAUL officer: Sr. V P, Asia Pacific
ResMed Options 9,000 N/A N/A
Option
EISEN PAUL officer: Sr. V P, Asia Pacific
ResMed Common Stock 9,000 N/A N/A
Sale
EISEN PAUL officer: Sr. V P, Asia Pacific
ResMed Common Stock 9,000 N/A N/A
Option
SMITH ADRIAN M officer: COO Europe
ResMed Common Stock 5,000 N/A N/A
Sale
SMITH ADRIAN M officer: COO Europe
ResMed Common Stock 5,000 N/A N/A
Option
SMITH ADRIAN M officer: COO Europe
ResMed Options 5,000 N/A N/A
Option
GALLAHUE KIERAN director, officer: Chief Execut..
ResMed Options 5,000 N/A N/A

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.